In January 2025, the SynThera project, focused on the development of synthetic therapeutic microbes for tailored antimicrobial therapies, was officially approved. The project is funded by the Carl Zeiss Foundation as part of their "CZS Durchbrüche" program. Involved are ten principal investigators from the Friedrich Schiller University Jena (FSU) and the Leibniz Institute for Natural Product Research and Infection Biology - Hans Knöll Institute (HKI).